ArticleDiscover oncology2025
Characterization of PANoptosis-related expression pattern, prognosis and tumor microenvironment in head and neck squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NDUFA4L2 regulates the progression and chemotherapy sensitivity of HNSCC by inhibiting PANoptosis.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveHead and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide with a poor prognosis. PANoptosis is a novel programmed cell death pathway. Presently, the expression pattern and prognosis of PANoptosis in HNSCC remain not fully elucidated.
methodsThe expression profile and corresponding clinical information were downloaded from The Cancer Genome Atlas Program (TCGA) and Gene Expression Omnibus (GEO). Univariate cox regression and consensus clustering analysis were applied to identify PANoptosis-related molecular subtypes. The subtype specific pathways were identify through gene set variation analysis (GSVA). The differentially expressed genes (DEGs) between subtypes were identified using limma algorithm. Then, a PANoptosis-related signature was constructed using univariate cox regression analysis and lasso analysis based on the DEGs. Kaplan-Meier (KM) and receiver operating characteristic (ROC) curves were exploited to evaluate the prognostic value of signature. In addition, the relationship between signature, immune microenvironment, and drug sensitivity was examined.
resultsA total of 707 tumor samples and 44 normal samples with corresponding clinical information were included in the study. Two molecular subtypes with distinct overall survival rates, immune cell infiltration and pathways were identified using clustering analysis. Compared to cluster N, cluster A was characterized by a favorable survival outcome and increasing immune cell infiltration. The TIDE analysis result indicated that patients in cluster A may have a better response to immunotherapy. In addition, a novel PANoptosis-related signature was constructed based on the DEGs from two clusters. The patients with high PANoptosis score were corresponding to a poor survival outcome. Cox regression analysis result revealed that the signature score could serve as an independent prognostic factors. Further drug analysis result suggest that patients in high PANoptosis group have more sensitivity to docetaxel drugs.
conclusionsThe two molecular subtypes and PANoptosis-related signature have the potential to underlying the molecular mechanism and provide reliable marker for the prognosis of HNSCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.